source
- BMS reports positive mid-stage results for arlo-cel in heavily pre-treated myeloma patientsBMS said its CAR T therapy arlo-cel, formally arlocabtagene autoleucel, achieved positive results in a registrational mid-stage study for relapsed and refractory multiple myeloma. The open-label,…
- Caspian Therapeutics launches with $50M funding and Eli Lilly backing to develop menin inhibitor for diabetesCaspian Therapeutics has been created as a spin-out from Kura Oncology to advance a menin-targeting drug for diabetes. The company received $50 million in initial capital, led by BVF Partners with…